Summary: Over the last five decades mucoactive agents have been successfully utilized in respiratory diseases of various etiology. Some of them have additional beneficial properties, making them particularly useful in treatment. The COVID-19 pandemic, where the major cause of severe course is coronaviral pneumonia, has generated additional interest in this particular group of medications. Potentially, they might be successfully used in supportive care. They have a relatively good safety profile. Some of them may also be delivered through nebulization devices (e.g. ambroxol hydrochloride).